An inquiry into the ImClone cancer-drug story: hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, June 13 and October 10, 2002, Volume 4
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
U.S. Government Printing Office, 2002 - Cetuximab - 759 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
antibody application approval Audit Committee Board of Directors Bristol Bristol-Myers Squibb Cancer Center cancer patients Cetuximab Chairman TAUZIN clinical trials colorectal cancer common stock Company Company's compensation Corporation counsel CRAWFORD December 27 December 31 DEGETTE disease documents dose EGFR employees Erbitux Executive Officer exercise Fast Track FDA's FLETCHER Goldhammer granted GREENWOOD HARLAN WAKSAL HCEC ImClone stock ImClone Systems Incorporated ImClone's Incentive Stock Option insider trading investigation irinotecan issues John Mendelsohn KEEGAN Kopperl loans MARKISON meeting Mendelsohn mg/m million monoclonal antibodies number of shares Okay oncology person prior protocol proxy proxy card purchase question received response SAMUEL WAKSAL securities shareholders shares of common shares of ImClone SMALDONE statement STEARNS stock options stockholders STUPAK Thank therapy Tippee toxicity transaction tumor VACZY Vice President vote WEISS York